The anaplastic lymphoma kinase testing conundrum

被引：6

作者：

Conde, Esther ^{[1
]}

Taniere, Philippe ^{[2
]}

Lopez-Rios, Fernando ^{[1
]}

机构：

[1] Univ San Pablo CEU, Fac Med, Hosp HM Univ Sanchinarro, Lab Dianas Terapeut, Madrid 28050, Spain

[2] Univ Hosp Birmingham Fdn Trust, Dept Cellular Pathol, Birmingham, W Midlands, England

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2015年 / 15卷 / 02期

关键词：

ALK; companion diagnostics; FISH; IHC; lung cancer; CELL LUNG-CANCER; ADENOCARCINOMA; CRIZOTINIB; INHIBITORS;

D O I：

10.1586/14737159.2015.997713

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Given the excellent results of the clinical trials with anaplastic lymphoma kinase (ALK) inhibitors, the importance of accurately identifying ALK-positive lung carcinoma patients has never been greater. It brings with it a pressing need for harmonized development of companion diagnostics, for economic, scientific and medical reasons. Therefore, it is crucial that ALK testing assays become more standardized both in performance (analytical phase) and interpretation (post-analytical phase). We find that both methods currently recommended by College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines (FISH and Immunohistochemistry) are reasonable approaches for primary routine ALK testing, if at least 50 tumor cells are scored and protocols are strictly followed. Moreover, due to the high demand to study multiple predictive biomarkers on different assay platforms, quick and reliable approaches to achieve this are essential to guide treatment decisions.

引用

页码：161 / 163

页数：3

共 15 条

[1] Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances [J].

Cabillic, Florian ;

Gros, Audrey ;

Dugay, Frederic ;

Begueret, Hugues ;

Mesturoux, Laura ;

Chiforeanu, Dan Cristian ;

Dufrenot, Leila ;

Jauffret, Vincent ;

Dachary, Dominique ;

Corre, Romain ;

Lespagnol, Alexandra ;

Soler, Gwendoline ;

Dagher, Julien ;

Catros, Veronique ;

Le Calve, Michele ;

Merlio, Jean-Philippe ;

Belaud-Rotureau, Marc-Antoine .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) :295-306

[2] Comprehensive molecular profiling of lung adenocarcinoma [J].

Collisson, Eric A. ;

Campbell, Joshua D. ;

Brooks, Angela N. ;

Berger, Alice H. ;

Lee, William ;

Chmielecki, Juliann ;

Beer, David G. ;

Cope, Leslie ;

Creighton, Chad J. ;

Danilova, Ludmila ;

Ding, Li ;

Getz, Gad ;

Hammerman, Peter S. ;

Hayes, D. Neil ;

Hernandez, Bryan ;

Herman, James G. ;

Heymach, John V. ;

Jurisica, Igor ;

Kucherlapati, Raju ;

Kwiatkowski, David ;

Ladanyi, Marc ;

Robertson, Gordon ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Sinha, Rileen ;

Sougnez, Carrie ;

Tsao, Ming-Sound ;

Travis, William D. ;

Weinstein, John N. ;

Wigle, Dennis A. ;

Wilkerson, Matthew D. ;

Chu, Andy ;

Cherniack, Andrew D. ;

Hadjipanayis, Angela ;

Rosenberg, Mara ;

Weisenberger, Daniel J. ;

Laird, Peter W. ;

Radenbaugh, Amie ;

Ma, Singer ;

Stuart, Joshua M. ;

Byers, Lauren Averett ;

Baylin, Stephen B. ;

Govindan, Ramaswamy ;

Meyerson, Matthew ;

Rosenberg, Mara ;

Gabriel, Stacey B. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Kim, Jaegil ;

Stewart, Chip .

NATURE, 2014, 511 (7511) :543-550

[3] Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers [J].

Conde, E. ;

Angulo, B. ;

Izquierdo, E. ;

Paz-Ares, L. ;

Belda-Iniesta, C. ;

Hidalgo, M. ;

Lopez-Rios, F. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (07) :503-508

[4] Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry [J].

Conde, Esther ;

Suarez-Gauthier, Ana ;

Benito, Amparo ;

Garrido, Pilar ;

Garcia-Campelo, Rosario ;

Biscuola, Michele ;

Paz-Ares, Luis ;

Hardisson, David ;

de Castro, Javier ;

Camacho, M. Carmen ;

Rodriguez-Abreu, Delvys ;

Abdulkader, Ihab ;

Ramirez, Josep ;

Reguart, Noemi ;

Salido, Marta ;

Pijuan, Lara ;

Arriola, Edurne ;

Sanz, Julian ;

Folgueras, Victoria ;

Villanueva, Noemi ;

Gomez-Roman, Javier ;

Hidalgo, Manuel ;

Lopez-Rios, Fernando .

PLOS ONE, 2014, 9 (09)

[5] The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre [J].

Conde, Esther ;

Angulo, Barbara ;

Izquierdo, Elisa ;

Munoz, Luna ;

Suarez-Gauthier, Ana ;

Plaza, Carlos ;

Dominguez, Nuria ;

Torres, Maribel ;

Madrigal, Luis ;

Rubio-Viqueira, Belen ;

Belda-Iniesta, Cristobal ;

Hidalgo, Manuel ;

Lopez-Rios, Fernando .

HISTOPATHOLOGY, 2013, 62 (04) :609-616

[6] Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review and Meta-Analysis [J].

Fan, Liang ;

Feng, Yun ;

Wan, Huanying ;

Shi, Guochao ;

Niu, Wenquan .

PLOS ONE, 2014, 9 (06)

[7] ALK inhibitors in the treatment of advanced NSCLC [J].

Gridelli, Cesare ;

Peters, Solange ;

Sgambato, Assunta ;

Casaluce, Francesca ;

Adjei, Alex A. ;

Ciardiello, Fortunato .

CANCER TREATMENT REVIEWS, 2014, 40 (02) :300-306

[8] "Companion Diagnostics": Has Their Time Come and Gone? [J].

Hirsch, Fred R. ;

Bunn, Paul A., Jr. ;

Herbst, S. .

CLINICAL CANCER RESEARCH, 2014, 20 (17) :4422-4424

[9]

Lindeman NI, 2013, ARCH PATHOL LAB MED, V137, P828, DOI [10.1097/JTO.0b013e318290868f, 10.5858/arpa.2012-0720-OA]

[10] Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non-Small-Cell Lung Cancer [J].

Peled, Nir ;

Palmer, Gary ;

Hirsch, Fred R. ;

Wynes, Murry W. ;

Ilouze, Maya ;

Varella-Garcia, Marileila ;

Soussan-Gutman, Lior ;

Otto, Geoff A. ;

Stephens, Philip J. ;

Ross, Jeffrey S. ;

Cronin, Maureen T. ;

Lipson, Doron ;

Miller, Vincent A. .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) :E14-E16

← 1 2 →